Australia markets close in 4 hours 49 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
28.31-1.33 (-4.49%)
At close: 04:00PM EST
28.31 0.00 (0.00%)
After hours: 04:46PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 4.63B
Enterprise value 4.01B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)7.68
Enterprise value/revenue N/A
Enterprise value/EBITDA -13.09

Trading information

Stock price history

Beta (5Y monthly) 1.58
52-week change 3-5.24%
S&P500 52-week change 3-11.32%
52-week high 341.46
52-week low 319.86
50-day moving average 327.90
200-day moving average 329.04

Share statistics

Avg vol (3-month) 3561.44k
Avg vol (10-day) 3364.04k
Shares outstanding 5156.32M
Implied shares outstanding 6N/A
Float 868.09M
% held by insiders 117.62%
% held by institutions 185.97%
Shares short (14 Nov 2022) 45.04M
Short ratio (14 Nov 2022) 48.74
Short % of float (14 Nov 2022) 410.87%
Short % of shares outstanding (14 Nov 2022) 43.22%
Shares short (prior month 13 Oct 2022) 45.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-22.24%
Return on equity (ttm)-51.57%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -320.4M
Net income avi to common (ttm)-317.76M
Diluted EPS (ttm)-1.71
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)989.92M
Total cash per share (mrq)6.34
Total debt (mrq)433.11M
Total debt/equity (mrq)71.78
Current ratio (mrq)16.64
Book value per share (mrq)3.86

Cash flow statement

Operating cash flow (ttm)-258.45M
Levered free cash flow (ttm)-143.59M